Clinical Trial

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.
Trial Details
NCT Number NCT07008703
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Cancer Pain
Enrollment 132 participants
Start Date 2024-03-27
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-06